



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad-500 033. INDIA.
Tel : +91 40 23547532, Fax : +91 40 23548243

28th May, 2012

The Manager - Listing
Corporate Relationship Department
The Bombay Stock Exchange Limited
Dalal Street, Fort
Mumbai 400 001.

Mr. Hari K
Vice President
M/s. National Stock Exchange of India Ltd
"Exchange Plaza", Bandra - Kurla Complex
Bandra (E) Mumbai 400 051.

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir,

Financial Results for the quarter ending March, 2012
and Audited Annual Accounts for the financial year 2011-2012

The Board of Directors of the Company at their meeting held today i.e. 28th May, 2012 considered and approved the financial results for the quarter ending March, 2012 along with Audited annual Accounts for the year 2011-2012 including the consolidated results along with segment wise Report for the said period. Please find enclosed copies of the same along with a copy of the Press note released in this connection.

Based on the recommendations of the Remuneration Committee of the Board of Directors, the Board, subject to the approval of members at the ensuing General Meeting, had revised the remuneration payable to Shri V.C.Nannapaneni, Chairman and Managing Director of the Company from Rs.96,00,000/- p.a.(Rupees ninety six lakhs only per annum) to Rs.1,25,00,000/- p.a.(Rupees one crore and twenty five lakhs only per annum) and redesignated Mr.Rajeev Nannapaneni as Vice Chairman & CEO besides increasing his remuneration from Rs.75,00,000/- p.a.(Rupees seventy five lakhs only per annum) to Rs.1,00,00,000/- p.a.(Rupees one crore only per annum) w.e.f.1-6-2012 for a period of three years.

This is for your information and records.

Thanking you,

Yours faithfully,
for NATCO Pharma Limited


Dr. P. Bhaskara Narayana
Director & Chief Financial Officer

Encl : As above.



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad-500 033. INDIA.
Tel : +91 40 23547532, Fax : +91 40 23548243

28th May, 2012

NATCO records increased revenues, profits !!!

The Hyderabad based NATCO Pharma Limited has recorded increased revenues and profits for the financial year ended on 31st March, 2012. The Board met at Hyderabad today and approved the accounts.

The Company has recorded aggregate revenues of Rs. 559 Crores (an increase of 15% over 2011- Rs. 484 Crores) and earned an after tax profit of Rs. 60 Crores (an increase of 12% over 2011 – Rs. 53 Crores).

The growth was driven by a 40% increase in API sales at Rs. 148 Crores from Rs. 106 Crores during 2011, a 22% increase in Formulation sales at Rs. 282 Crores in 2012 from 232 Crores in 2011. The company's oncology division performed well, recording an increase in sales from Rs. 121 Crores in 2011 to Rs. 148 Crores in 2012. The company's exports aggregated to Rs. 183 Crores, an increase of 37% over that of 2011 (Rs. 134 Crores).

Forwarded for favor of publication

For NATCO Pharma Limited.


Dr. Bhaskara Narayana, P.
Director & Chief Financial Officer



Statement of consolidated Financial Results for the quarter and year ended 31st March, 2012

Rs. lakhs

PARTICULARS (REFER NOTES BELOW)	THREE MONTHS ENDED (UNREVIEWED/UNAUDITED)			YEAR ENDED (AUDITED)	
	31-MAR-2012	31-DEC- 2011	31-MAR-2011	31-MAR-2012	31-MAR-2011
01. Net Sales / Income from Operations (including Excise Duty & Sales Tax)	14166	13596	10628	51845	44943
02. Other Operating Income	1218	947	902	3713	3364
03. TOTAL INCOME FROM OPERATIONS	15384	14543	11530	55558	48307
04. EXPENDITURE					
a) Cost of materials consumed	5372	4617	3747	18660	18276
b) Purchases of stock-in-trade	330	293	636	1553	1672
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-42	252	-456	75	-1148
d) Employee benefits expense	2176	2049	1553	7777	6407
e) Depreciation and amortization expense	166	408	401	1583	1474
f) Other Expenses	4965	4217	3828	15944	13657
TOTAL EXPENSES	12967	11836	9709	45592	40338
05. Profit / (Loss) from Operations before other income, finance costs and exceptional items	2417	2707	1821	9966	7969
06. Other Income	74	35	45	350	135
07. Finance costs	621	581	401	2382	1576
08. Profit / (Loss) from ordinary activities before tax	1870	2161	1465	7954	6528
09. Tax expense, including deferred tax	619	504	42	2107	1321
10. Minority Interest	-14	-43	-15	-114	-144
11. Net Profit / Loss (-) from ordinary activities after tax	1265	1700	1438	5961	5351
12. Paid-up Equity Share Capital (each share of Rs. 10/- face value)	3115	3115	2815	3115	2815
13. Reserves excluding revaluation reserves as per Balance Sheet of previous accounting year				44086	32429
14. Earnings per share – Basic and diluted EPS before and after extraordinary item (Rs.)	4.35	5.91	5.11	20.53	19.01
	4.35	5.91	5.11	20.53	19.01
15. Public Shareholding:					
a) Number of Shares	13,378,081	13,389,871	10,459,455	13,378,081	10,459,455
b) Percentage of Shareholding	42.95	42.99	37.16	42.95	37.16
16. Promoters and Promoter Group Shareholding					
a) Pledged / Encumbered – No. of shares	-	-	1,050,000	-	1,050,000
Percentage (as a % of the total shareholding of promoter and promoter group)	-	-	5.94	-	5.94
Percentage (as a % of the total share capital of the company)	-	-	3.73	-	3.73
b) Non – encumbered – No. of shares					
Percentage (as a % of the total shareholding of promoter and promoter group)	17,769,881	17,758,081	16,638,497	17,769,881	16,638,497
Percentage (as a % of the total share capital of the company)	100.00	100.00	94.06	100.00	94.06
	57.05	57.01	59.11	57.05	59.11

The above financial results were reviewed / audited by the statutory auditors of the Company, the Audit Committee and approved by the Board of Directors at a meeting held at Hyderabad, on Monday, the 28th May, 2012. The net sales / income from operations include sales tax of (Rs. lakhs) 304, 311, 213, 1123, 854 and excise duty of (Rs. lakhs) 82, 107, 115, 307, 264 and other operating income includes excise rebate of (Rs. Lakhs) 129, 155, 182, 656, 550 respectively for the quarters ended on 31st March, 2012, 31st December, 2011, and 31st March, 2011. and for the year ended on 31st March, 2012 and 2011. There are no exceptional and extraordinary items to be reported for the period under review. Figures for the previous period(s) have been re-arranged / re-grouped wherever necessary. Figures for the quarter ended on 31st March are the balancing figures between audited figures in respect of the full financial year and the published year to date figures upto the third quarter of the financial year. The stand-alone results are available on the company's web-site www.natcopharma.co.in. In respect of reference relating to non-accounting of minimum alternate tax credit, in the Auditors' Report, the company will review the position during the current financial year.

Dated at Hyderabad, this, the 28th day of May, 2012.
for and on behalf of the Board of Directors,
NATCO Pharma Limited

Dr. P. Bhaskara Narayanan
Director & Chief Financial Officer

Status of Investor Complaints as at 31st March, 2012

Pending as on 01-10-2012	Nil
Resolved during the quarter	49
Pending as on 31-03-2012	Nil



Consolidated Statement of Assets and Liabilities (Rs. in lakhs)

Particulars	As at 31-Mar-2012	As at 31-Mar-2011
Equity & Liabilities		
Shareholders' Funds		
a) Share Capital	3115	2815
b) Reserves & Surplus	44086	32429
c) Money received against share warrants	-	-
Sub-total : Shareholders' funds	47201	35244
Share application money pending allotment	-	-
Minority Interest	88	106
Non-current liabilities		
a) Long term borrowings	13979	12427
b) Deferred tax liabilities (net)	2889	2509
c) Other long-term liabilities	135	125
d) Long term provisions	978	1002
Sub-total : Non-current Liabilities	17981	16063
Current Liabilities		
a) Short term borrowings	8100	7202
b) Trade payables	10957	9494
c) Other current liabilities	7429	3930
d) Short-term provisions	66	12
Sub-total : Current Liabilities	26552	20638
TOTAL – EQUITY AND LIABILITIES	91822	72051
Assets		
Non-current Assets		
a) Fixed Assets	49026	35694
b) Goodwill on consolidation	-	-
c) Non-current investments	6179	6179
d) Deferred tax assets (net)	-	-
e) Long term loans and advances	4627	4384
f) Other non-current assets	42	96
Sub-toital : Non-current Assets	59874	46353
Current Assets		
a) Current Investments	74	82
b) Inventories	11039	10223
c) Trade receivables	9469	7098
d) Cash and cash equivalents	3288	3237
e) Short term loans and advances	7965	5047
f) Other current assets	113	11
Sub-total : Current Assets	31948	25698
TOTAL – ASSETS	91822	72051